February 2021

Donald M. Berwick, MD, MPP, the former CMS administrator who is president emeritus and senior fellow at the Institute for Healthcare Improvement, discusses cost variation in cancer care found through the digital classification system the COTA Nodal Address.

An ideal alternative payment model would reward radiation oncologists for participation in a value-based payment arrangement that grants them the freedom to make care delivery decisions based on patient needs and in accordance with clinical guidelines, says ASTRO's Anne Hubbard, MBA.

ACCC president Randall Oyer, MD, gives insight into the ongoing collaboration between the ACCC and ASCO to foster minority participation in cancer clinical trials.

In this issue of Evidence-Based Oncology™ we see a foreshadowing of what the future of cancer care innovation could look like and how we may learn to move forward, safely, at an ever-accelerating pace.

Excitement around gene therapy is back and greater than before. Although safety remains a concern, investigators are breaking ground in cell and gene therapy, and many believe that ultimately, a string of cancer cures will follow.

Tanya Siddiqi, MD, director of the chronic lymphocytic leukemia program at Toni Stephenson Lymphoma Center provides insights on what the arrival of liso-cel could mean in the treatment landscape.

The new indication for osimertinib (Tagrisso) marks the first FDA approval of an adjuvant treatment for non–small cell lung cancer (NSCLC) with EGFR exon 19 deletions or exon 21 L858R mutations.

A recent study investigated what makes some non-small cell lung cancer patients with a type of human leukocyte antigen (HLA) called B44 are more likely than others to respond to immunotherapy.

Researchers from the Children’s Medical Center Research Institute at the University of Texas Southwestern discovered a potential treatment for patients with non–small cell lung cancer (NSCLC) who have KRAS and LKB1 mutations.

To ensure that value assessment accounts for patient needs, we need a better understanding of the outcomes that are most important to patients, write authors from COVIA Health Solutions and the University of Washington School of Pharmacy.

Patients with ovarian cancer who lived within 10 miles of Kansas’s only National Cancer Institute–designated cancer center, and those of a non-White race, were shown to have less of a survival advantage.

Deferred low-dose computed tomography lung cancer screening during the coronavirus disease 2019 (COVID-19) pandemic has worsened outcomes for patients with lung cancer, a new study found.

The study, presented at the 2020 San Antonio Breast Cancer Symposium, also found that time to first treatment dropped during this period of the coronavirus disease 2019 (COVID-19) pandemic.

Older adults with acute myeloid leukemia (AML) saw increased overall and relapse-free survival, as well as preserved quality of life, following oral administration of 300-mg azacitidine.

The newly approved expanded label includes data from the final analysis of the phase 3 iNNOVATE study of ibrutinib plus rituximab vs rituximab alone.

Genentech's tiragolumab, a novel immunotherapy for non-small cell lung cancer with PD-L1 expression, is the first anti-TIGIT therapy to be granted Breakthrough Therapy Designation.

Experts in gynecologic oncology and genitourinary oncology discuss the current state of PARP inhibitors in prostate and ovarian cancers.

Home administration of oral paclitaxel and encequidar is associated with potential cost savings for payers compared with clinic administration of intravenous chemotherapy in metastatic breast cancer patients.

Home administration of oral paclitaxel and encequidar is associated with potential cost savings for payers compared with clinic administration of intravenous chemotherapy in metastatic breast cancer patients.